Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5413636 | 0.84 | ADORA2A (0.79) | ADORA2AADORA1 | |
| SCHEMBL5411271 | 0.84 | ADORA2A (0.71) | ADORA2AADORA1 | |
| SCHEMBL5418082 | 0.83 | ADORA2A (0.75) | ADORA2AADORA1 | |
| SCHEMBL5416057 | 0.83 | ADORA2A (0.68) | ADORA2AADORA1 | |
| SCHEMBL5407836 | 0.83 | ADORA2A (0.70) | ADORA2AADORA1 | |
| SCHEMBL5424843 | 0.82 | ADORA2A (0.67) | ADORA2AADORA1 | |
| SCHEMBL5426610 | 0.82 | ADORA2A (0.82) | ADORA2AADORA1 | |
| SCHEMBL5410628 | 0.82 | ADORA2A (0.85) | ADORA2AADORA1 | |
| SCHEMBL5420373 | 0.81 | ADORA2A (0.69) | ADORA2AADORA1 | |
| SCHEMBL5417223 | 0.81 | ADORA2A (0.72) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1949903-B1 | SELECTIVE A2A RECEPTOR ANTAGONISTS FOR THE TREATMENT OF AURICULAR FIBRILLATION | PROYECTO BIOMEDICINA CIMA SL (ES) | 2012-04-18 | — | — | EP | disclosed |
| US-8012973-B2 | Compounds for the treatment of auricular fibrillation | PROYECTO DE BIOMEDICINA CIMA S.L. (ES) | 2011-09-06 | — | — | US | disclosed |
| US-8012973-B2 | Compounds for the treatment of auricular fibrillation | PROYECTO DE BIOMEDICINA CIMA S.L. (ES) | 2011-09-06 | — | — | US | disclosed |
| US-20090312332-A1 | COMPOUNDS FOR THE TREATMENT OF AURICULAR FIBRILLATION | PROYECTO DE BIOMEDICINA CIMA, S.L. (ES) | 2009-12-17 | — | — | US | disclosed |
| US-20090312332-A1 | COMPOUNDS FOR THE TREATMENT OF AURICULAR FIBRILLATION | PROYECTO DE BIOMEDICINA CIMA, S.L. (ES) | 2009-12-17 | — | — | US | disclosed |
| EP-1949903-A2 | COMPOUNDS FOR THE TREATMENT OF AURICULAR FIBRILLATION | Proyecto de Biomedicina Cima, S.L. (ES) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007045705-A2 | COMPOUNDS FOR THE TREATMENT OF AURICULAR FIBRILLATION | PROYECTO DE BIOMEDICINA CIMA, S.L. (ES) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312332-A1 | COMPOUNDS FOR THE TREATMENT OF AURICULAR FIBRILLATION | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.